AB Science collapses on the stock market after key clinical trial failure
AB Science's stock plunges 45% after announcing negative results for its cancer treatment.
Published 6sem1 sourceImportantupdated 3j
Lire en français
≈ 20s
The fact
The phase 3 trial failed to meet its primary efficacy endpoint.
The French biotech loses 1.2 billion euros in market capitalization in a single session.
Click the link to read an article on the topic: